These three companies from the BioRegion were recognized by the Terrassa Chamber of Commerce for their strategy based on innovation, training and knowledge.
Diabetic retinopathy is the most commonly associated disease with diabetes. It has a worldwide incidence of more than 11.5 million people in Europe, USA and Japan.
The project will develop a new 'lab-on-a-chip' device to improve diagnostics and treatment of this disease, which is transmitted by ticks.
This capital increase will fund development of a 'Point of Care' diagnostic platform.
It is located in Hertfordshire (United Kingdom) at the BioPark cluster, only a year later the opening of its first international office in Germany.
Díaz-Varela will contribute his ample experience in the pharmaceutical sector, which is key as Avancell currently has a variety of projects in the licensing phase.
This biotech firm has reached two great milestones in 2010: launching their first products to market and being traded on the Alternative Stock Market.
Dr. Solà-Morales will take on responsibilities related to clinical development and product regulations in the company.
Some 56% are in biotechnology and 22% in nanotechnology and industrial processes. Most of the companies are Catalan.
This is the first DPP-4 inhibitor to be approved in a single dose, without the need to adjust the dose in type-2-diabetes patients with renal or hepatic deterioration.
Developed by Drauta